Walleye Capital
APLS

Walleye Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Walleye Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$129K Sell
3,200
-4,300
-57% -$92.7K ﹤0.01% 3562
2025
Q4 		$188K Buy
7,500
+2,900
+63% +$68K ﹤0.01% 3565
2025
Q3 		$104K Sell
4,600
-2,900
-39% -$67.6K ﹤0.01% 3701
2025
Q2 		$130K Buy
7,500
+7,000
+1,400% +$130K ﹤0.01% 3641
2025
Q1 		$10.9K Sell
500
-2,300
-82% -$63.5K ﹤0.01% 4059
2024
Q4 		$89.3K Buy
2,800
+2,600
+1,300% +$78.2K ﹤0.01% 4182
2024
Q3 		$5.77K Sell
200
-1,600
-89% -$59.3K ﹤0.01% 4984
2024
Q2 		$69K Sell
1,800
-25,400
-93% -$1.15M ﹤0.01% 4845
2024
Q1 		$1.6M Buy
27,200
+10,000
+58% +$637K ﹤0.01% 2161
2023
Q4 		$1.03M Sell
17,200
-100
-0.6% -$5.07K ﹤0.01% 2314
2023
Q3 		$658K Buy
17,300
+8,900
+106% +$391K ﹤0.01% 2599
2023
Q2 		$765K Buy
8,400
+6,100
+265% +$526K ﹤0.01% 2073
2023
Q1 		$152K Sell
2,300
-6,800
-75% -$392K ﹤0.01% 2679
2022
Q4 		$471K Buy
9,100
+7,800
+600% +$414K 0.01% 1492
2022
Q3 		$89K Buy
+1,300
New +$76.9K ﹤0.01% 2462
2020
Q2 		– Sell
-14,600
Closed -$391K – 609
2020
Q1 		$391K Buy
+14,600
New +$518K 0.09% 275

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Walleye Capital's APLS Position: Q1 2026 in Review

Walleye Capital reduced its Apellis Pharmaceuticals (APLS) stake by 17% in Q1 2026, selling an estimated $14.3K and leaving 3,290 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #3548.

Walleye Capital first reported a position in APLS in Q4 2021 and has held it in 15 quarters since. The position peaked at $12.6M in Q4 2024. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Walleye Capital held 3,290 shares of Apellis Pharmaceuticals worth $132K as of Q1 2026.
  • Walleye Capital sold 665 Apellis Pharmaceuticals shares in Q1 2026, an estimated $14.3K.
  • Apellis Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3548 holding.
  • Walleye Capital first reported a position in Apellis Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • Walleye Capital's Apellis Pharmaceuticals position peaked at $12.6M in Q4 2024.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.